C3

(redirected from C-3)
Also found in: Dictionary, Acronyms, Encyclopedia.

C3

A diagnostic category based on the NHSBSP guidelines for reporting FNAC (fine needle aspiration cytology) of breast lesions. C3s have most of the characteristics described in C2s, but also have features not usually present in benign smears and have one or more of the following features:
(1) Crowded, enlarged nuclei with overlapping in three-dimensional groups or sheets;
(2) Loss of cellular cohesion;
(3) Nuclear pleomorphism;
(4) Chromatin clumping.
 
C3 cellularity may be normal or increased and large bare nuclei may be seen, as well as nuclear pleomorphism and dissociation.

Examples, C3
Epithelial hyperplasia with or without atypia, fibroadenoma/fibroadenomatoid change, gynaecomastia, papilloma, hormonal changes, radial scar, atypical apocrine lesion, columnar cell change, lobular lesions (e.g., atypical lobular hyperplasi), certain carcinomas (e.g., tubular carcinoma, cribriform carcinoma).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

complement deficiency

A state in which any of the complement proteins is subnormal
Complement deficiencies–associated disorders
C1
C1r    SLE, renal disease, repeated infections
C1s    SLE
C2    SLE, vasculitis, membranoproliferative glomerulonephritis, dermatomyositis
C3 Repeated infections
C4 SLE
C5 SLE, gonococcal disease
C6 Relapsing meningococcal meningitis, gonococcal infection
C7 Raynaud's disease, chronic renal disease, gonococcal infection
C8 SLE, gonococcal infection
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

C3

The most abundant and functionally diverse component of the complement system.C3 has two main allotypes F (fast) and S (slow). In kidney transplant patients it has been found that C3 S/S recipients have a better long-term outcome when grafted with a C3 F/F or a C3 F/S/ kidney than with a C3 S/SF kidney.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
of aliphatic), 1649 (C=O str.), 1581 (C=C aromatic str.), 1430 (S=O), 1195 (C-O-C bond str.), 1114 (C-N-C bond str.); 1H-NMR (600 MHz, CDCl3, I', ppm): 7.84 (d, J = 2.4 Hz, 1H, H-6"), 7.64 (d, J = 2.5 Hz, 1H, H-4"), 7.49 (d, J = 1.5 Hz, 1H, H-5), 7.02 (d, J = 3.5 Hz, 1H, H-3), 6.56 (dd, J = 1.4, 3.6 Hz, 1H, H-4), 4.55 (m, 1H, H-2'"), 3.90 (br.s, 4H, CH2-3', CH2-5'), 3.34 (br.t, J = 4.9 Hz, 4H, CH2-2', CH2-6') 1.05 (d, J = 6.7 Hz, 6H, CH3-1'", CH3-3'"); 13C-NMR (150 MHz, CDCl3, I', ppm): 159.41 (C-2"), 152.65 (C-6), 147.16 (C-2), 143.53 (C-5), 134.96 (C-4"), 134.37 (C-5"), 131.36 (C-6"), 129.53 (C-1"), 126.57 (C-3"), 116.56 (C-3), 111.65 (C-4), 67.04 (C-1'''), 46.77 (C-2', C-3', C-5', C-6'), 20.53 (C-2''', C-3'''); Anal.
and pre-operational tests, C-3 and C-4 submitted application for issuance of operating license.
149-151[degrees]C; IR (KBr, [cm.sup.-1]): 1652 (C=O), 1585 (C=C of Ar), 1503 (CH=CH), 2959 (Ar C-H), 2713 (Alkyl C-H); 1H NMR (400 MHz, CD[Cl.sub.3], ppm): d 7.19 (1H, d, J = 17 Hz, -CO-CH=), 7.79 (1H, d, J = 17 Hz, =CH-Ar), 6.89-7.85 (7H, Ar-H), 1.01 (6H, d, J = 8 Hz, -[(C[H.sub.3]).sub.2]), 2.05-2.22 (1H, m, -CH-), 2.62 (2H, d, J = 8 Hz, -C[H.sub.2]-); [sup.13]C NMR (100 MHz, CD[Cl.sub.3], ppm): [delta] 189.88 (C-1), 127.58 (C-2), 131.43 (C-3), 130.21 (C-2' and C-6 '), 128.95 (C-3' and C-5'), 135.13 (C-1'), 146.88 (C-4'), 154.81 (C-2"), 114.38 (C-3"), 114.67 (C-4"), 123.12 (C-5"), 22.65 (-C[H.sub.3], C of isobutyl group at C-4 "), 29.81 (-CH-, C of isobutyl group at C-4"), 46.66 (-C[H.sub.2]-, C of isobutyl group at C-4"); MS (m/z, %): 334.2 (M + 1, 99.42); Anal.
This announcement came as the company plans to open the first phase of Segment 10-running from Karuhatan, Valenzuela City, to the new Caloocan Interchange in C-3 Road-on February 26.
Completing the segment is a four-lane elevated road from C-3 Road, Caloocan City to R-10, Navotas City.
mass: 254 gmol-1; IR (KBr, max/cm-1): 3249 (O-H), 3045 (Ar C-H), 1664 (C=N), 1617 (Ar C=C); 1H- NMR (400 MHz, CD3OD, d in ppm): 8.03 (s, 1H, H- 7'), 7.94 (dd, J = 7.6, 1.6 Hz, 2H, H-2' and H-6'), 7.74- 7.69 (m, 3H, H-3' to H-5'), 7.25 (d, J = 8.4 Hz, 1H, H-6), 6.27 (dd, J = 8.4, 2.0 Hz, 1H, H-5), 6.23 (d, J = 2.0 Hz, 1H, H-3), 2.14 (s, 3H, CH3-8); 13C-NMR (100 MHz, CD3OD, d in ppm): 171.3 (C-7), 165.8 (C-2), 163.6 (C-4), 153.4 (C-7'), 139.2 (C-1'), 132.4 (C-6), 130.5 (C-3' and C-5'), 128.7 (C-4'), 124.6 (C-2' and C-6'), 109.9 (C-5), 108.4 (C-1), 106.1 (C-3), 15.3 (C-8); EIMS (m/z): 254 [M]+, 109 [C6H5O2]+, 108 [C6H4O2]+, 104 [C7H6N]+, 83 [C4H3O2]+, 80 [C5H4O]+, 77 [C6H5]+, 67 [C4H3O]+, 51 [C4H3]+.
A reserving component of C-3, Phase II for VAs is currently being developed by the American Academy of Actuaries, Washington, to complement the C-3, Phase II RBC par of the project.
When this is completed, travel time from C-3 in Caloocan City and Nlex, will be reduced to 10 minutes,' Villar said in a news statement.
The NMR data of compound 6 afforded two methoxyl groups which could be fixed at C-6 and C-3, whereas, compound 7 also afforded two methoxyl units, which were placed at C-7 and C-3 through HMBC correlations.